Aardvark Therapeutics Inc. Common Stock (AARD)
Stock · NASDAQ · Health Care
$3.77as of 10/16/2026
Price chart
Active signals
AARD Signal Track Record
How signals performed across all stocks →What AARD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 7 | +4.0% | 57% | October 6, 2026 |
| Bollinger Band Breakout | 7 | +4.0% | 57% | August 7, 2026 |
| Bollinger Band Breakdown | 4 | -24.7% | 0% | October 8, 2026 |
| Any 20-session window (baseline) | -6.4% | 43% |
Computed by MarketWall from daily closing prices since November 28, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 28
- Website
- aardvarktherapeutics.com/
Fundamentals
- 1-day range
- $3.73$4.19
- Market cap
- $159.75M
- P/E (trailing)
- —
- P/E (forward)
- -1.59
- EPS (trailing)
- $-3.21
- Dividend yield
- —
- Beta
- 3.81
- Avg. volume
- 132.1K
Forecasts
9 analyst ratings
Aardvark Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AARDAardvark Therapeutics Inc. Common Stock$3.78▼ 2.07%Market cap $159.75MP/E —$3.35$16.6
- NKTXNkarta Inc. Common Stock$1.8▼ 6.74%Market cap $163.84MP/E —$1.7$3.72
- MENSJyong Biotech Ltd. Ordinary Shares$1.84▼ 7.07%Market cap $153.58MP/E —$1.43$63
- INDPIndaptus Therapeutics Inc. Common Stock$2.63▼ 7.72%Market cap $166.55MP/E —$0.92$5.96
- PEPGPepGen Inc. Common Stock$2.6▲ 2.77%Market cap $166.70MP/E —$1.31$7.8
- OKUROnKure Therapeutics Inc. Class A Common Stock$2.1▼ 1.41%Market cap $168.06MP/E —$2.13$5.38
- MISTMilestone Pharmaceuticals Inc. Common Shares$0.707▼ 11.07%Market cap $146.91MP/E —$0.7075$3.06
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AARD Aardvark Therapeutics Inc. Common Stock | $159.75M | — | $3.78 | ▼ 2.07% | $3.35$16.6 |
| NKTX Nkarta Inc. Common Stock | $163.84M | — | $1.8 | ▼ 6.74% | $1.7$3.72 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $153.58M | — | $1.84 | ▼ 7.07% | $1.43$63 |
| INDP Indaptus Therapeutics Inc. Common Stock | $166.55M | — | $2.63 | ▼ 7.72% | $0.92$5.96 |
| PEPG PepGen Inc. Common Stock | $166.70M | — | $2.6 | ▲ 2.77% | $1.31$7.8 |
| OKUR OnKure Therapeutics Inc. Class A Common Stock | $168.06M | — | $2.1 | ▼ 1.41% | $2.13$5.38 |
| MIST Milestone Pharmaceuticals Inc. Common Shares | $146.91M | — | $0.707 | ▼ 11.07% | $0.7075$3.06 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of DirectorsYahoo · 10/8/2026
- Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price TargetBenzinga · 9/24/2026
- Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Zhang Zhongwei · October 7, 2026 · Grant127.1K
- Sun Nelson · September 11, 2026 · Sale62.0K @ $5.18
- Sun Nelson · September 10, 2026 · Sale14.8K @ $5
- Chi Jeffrey · August 14, 2026 · Grant45.0K
- Tong Victor Edward Jr · August 14, 2026 · Grant45.0K
- Roy D. Baynes · August 14, 2026 · Grant45.0K
- Graf Susan E · August 14, 2026 · Grant45.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 10.10M
- Total value held
- $37.98M
- Institutional holders
- 76
- Unknown3.92M
- Unknown1.30M
- Unknown1.03M
- Unknown792.6K
- Unknown554.1K
- Unknown316.6K
- Unknown309.4K
- Unknown300.0K
- Unknown199.3K
- Unknown163.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD)
RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.